Sona NanotechSNANF 26 Pretax Margin % is % as of Jan. 2026. GuruFocus rates SNANF with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 202 Medical Diagnostics & Research companies, Sona Nanotech ranks worse than 495049.01% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Sona Nanotech's Pre-Tax Income for the
three
months ended in Jan. 2026 was $-0.48 Mil. Sona Nanotech's Revenue for the
three
months ended in Jan. 2026 was $0.00 Mil. Therefore, Sona Nanotech's pretax margin for the quarter that ended in Jan. 2026 was %.
The historical rank and industry rank for Sona Nanotech's Pretax Margin % or its related term are showing as below:
SNANF's Pretax Margin % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -3.565 * Ranked among companies with meaningful Pretax Margin % only.
Sona Nanotech (OTCPK:SNANF) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Sona Nanotech Pretax Margin % Related Terms
Sona Nanotech Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Sona Nanotech's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SNANF vs TMO, DHR, IDXX: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, Sona Nanotech's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sona Nanotech Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sona Nanotech's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Sona Nanotech's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sona Nanotech (SNANF) has a Pretax Margin % of % as of Jan. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Sona Nanotech and its competitors. According to the industry distribution chart, Sona Nanotech ranks #999999 out of 202 companies in the Medical Diagnostics & Research industry.
Is Sona Nanotech's Pretax Margin % too high?
Sona Nanotech's current Pretax Margin % is %. Based on the distribution chart, Sona Nanotech ranks #999999 out of 202 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Sona Nanotech has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Sona Nanotech's Pretax Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Sona Nanotech ranks #999999 out of 202 companies for Pretax Margin %. This places Sona Nanotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Sona Nanotech and its competitors. Sona Nanotech's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sona Nanotech stock overvalued right now?
Sona Nanotech (SNANF) has a current Pretax Margin % of %. The current Pretax Margin % is %. Sona Nanotech's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Sona Nanotech (SNANF), the current Pretax Margin % is % as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sona Nanotech Inc is involved in the nanotechnology life sciences industry. It has developed two proprietary methods for the manufacture of rod-shaped gold nanoparticles and is engaged in the research and development of its proprietary technology for use in biomedical applications and multiplex diagnostic testing platforms. The company is using its gold nano rods manufacturing technology to develop new products and methods for cancer treatment, including a Targeted Hyperthermia Therapy (THT). Additionally, it has filed patent applications in the U.S. regarding a gold nanorod conjugation concept for targeted drug delivery, combination therapies for treating cancer, and for an endoscope with an optical fibre and thermal sensor for photothermal therapy.
26GF Score
Get the complete analysis for SNANF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNANF has been successfully added to your 
